The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lullan     (3aR,7aS)-2-[4-[4-(7-thia-8...

Synonyms: Perospirone, SureCN1155757, ACN-S001249, SM-9018, CCG-100862, ...
This record was replaced with 115368.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lullan


Psychiatry related information on Lullan

  • 2. SM-9018 treatment (10 mg/kg/day p.o.) for 2 weeks did not significantly change the density (Bmax) of striatal D2 receptors or the incidence of stereotyped behavior induced by apomorphine (APO) [3].

High impact information on Lullan


Chemical compound and disease context of Lullan

  • 3. The incidence of the apomorphine-induced stereotyped behaviors (e.g., sniffing, chewing, licking and biting) was negligibly affected by SM-9018 treatment, but was markedly enhanced by haloperidol treatment [2].

Biological context of Lullan

  • 5. These findings suggest that SM-9018 is weaker than HAL in inducing up-regulation and supersensitivity of the striatal D2 receptors after the subchronic treatment [3].

Anatomical context of Lullan


Gene context of Lullan


  1. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Ohno, Y., Ishida, K., Ikeda, K., Ishibashi, T., Okada, K., Nakamura, M. Pharmacol. Biochem. Behav. (1994) [Pubmed]
  2. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats. Ohno, Y., Ishida, K., Ishibashi, T., Ikeda, K., Kato, T., Nakamura, M. Gen. Pharmacol. (1995) [Pubmed]
  3. Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats. Ohno, Y., Ishibashi, T., Okada, K., Ishida, K., Nakamura, M. Prog. Neuropsychopharmacol. Biol. Psychiatry (1995) [Pubmed]
  4. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Ishibashi, T., Ikeda, K., Ishida, K., Yasui, J., Tojima, R., Nakamura, M., Ohno, Y. Eur. J. Pharmacol. (1996) [Pubmed]
  5. Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats. Maruoka, Y., Ohno, Y., Kato, T., Hirose, A., Tatsuno, T., Nakamura, M. Jpn. J. Pharmacol. (1993) [Pubmed]
WikiGenes - Universities